1. Home
  2. ADCT vs NMAI Comparison

ADCT vs NMAI Comparison

Compare ADCT & NMAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$3.85

Market Cap

484.4M

Sector

Health Care

ML Signal

HOLD

Logo Nuveen Multi-Asset Income Fund of Beneficial Interest

NMAI

Nuveen Multi-Asset Income Fund of Beneficial Interest

HOLD

Current Price

$13.72

Market Cap

433.5M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADCT
NMAI
Founded
2011
2021
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
484.4M
433.5M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
ADCT
NMAI
Price
$3.85
$13.72
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$7.75
N/A
AVG Volume (30 Days)
641.0K
101.7K
Earning Date
05-13-2026
01-01-0001
Dividend Yield
N/A
13.14%
EPS Growth
30.86
N/A
EPS
N/A
0.64
Revenue
$81,357,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$66.49
N/A
P/E Ratio
N/A
$21.30
Revenue Growth
14.85
N/A
52 Week Low
$1.13
$11.31
52 Week High
$4.98
$13.96

Technical Indicators

Market Signals
Indicator
ADCT
NMAI
Relative Strength Index (RSI) 49.84 69.14
Support Level $3.41 $13.43
Resistance Level $4.71 $13.90
Average True Range (ATR) 0.21 0.24
MACD 0.01 0.18
Stochastic Oscillator 66.92 98.55

Price Performance

Historical Comparison
ADCT
NMAI

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

About NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest

Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund's investment objective is to provide total return through high current income and capital appreciation.

Share on Social Networks: